Itano Junko, Higo Hisao, Ohashi Kadoaki, Makimoto Go, Nishii Kazuya, Hotta Katsuyuki, Miyahara Nobuaki, Maeda Yoshinobu, Kiura Katsuyuki
Department of Respiratory Medicine, Okayama University Hospital, Japan.
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Intern Med. 2020 Mar 15;59(6):823-828. doi: 10.2169/internalmedicine.3689-19. Epub 2019 Nov 29.
Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced interstitial lung disease (OsiILD) with an organizing pneumonia (OP) pattern and provide a literature-based review. Six months after osimertinib administration, a 75-year-old woman with right pleural carcinomatosis developed ILD with an OP pattern. After salvage chemotherapy, osimertinib with corticosteroid was successfully re-administered. A literature review suggested that 1) OsiILD with an OP pattern was rare but should be recognized, and 2) re-administration of osimertinib in OsiILD was successful in select patients. A criterion that determines whether a patient would benefit from re-administration is warranted.
奥希替尼是表皮生长因子受体（EGFR）突变型肺癌的标准治疗药物。我们在此报告一例奥希替尼诱发的具有机化性肺炎（OP）模式的间质性肺病（OsiILD）病例，并进行基于文献的综述。在使用奥希替尼6个月后，一名患有右胸膜癌病的75岁女性出现了具有OP模式的ILD。在挽救性化疗后，奥希替尼联合皮质类固醇成功再次给药。文献综述表明，1）具有OP模式的OsiILD很少见，但应予以识别；2）在部分患者中，OsiILD患者再次使用奥希替尼是成功的。确定患者是否能从再次给药中获益的标准是必要的。
